On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...

The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

The prime ministers of Malaysia and Pakistan have agreed to increase bilateral trade and boost economic ties after talks in ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Focus changed how many fans followed the NFL by providing grades and advanced statistics to help quantify how every player ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

Crayon, a global leader in IT optimization and AI services, is proud to announce that Regina Manfredi, Executive Vice President and General Manager, has been named a finalist in the Executive Mentor ...

As the hostilities in the wider Middle East escalate, 7 October 2024 marks one-year since the Hamas-Israel conflict began. Israel's response escalated into conflicts with other organisations, ...

(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.

Sep. 18, 2024 — A team of scientists alarmed by the loss of biodiversity across the world due to climate change has proposed a new approach to managing vulnerable ... Rugged Falklands Landscape ...

AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...